Associations between ABO blood groups and biochemical recurrence after radical prostatectomy

International Journal of Clinical and Experimental Medicine

Naoya Satake¹  Hidenori Okubo¹  Riu Hamada¹  Masaaki Tachibana¹  Makoto Ohori¹  Jun Nakashima¹  Yoshihiro Nakagami¹  Issei Takizawa¹  Yoshio Ohno¹  Kunihiko Yoshioka¹  Takeshi Hashimoto¹ 

关键词: ABO blood groups;    prostate cancer;    radical prostatectomy;    prognosis;    biochemical recurrence;   

DOI  :  

学科分类：医学（综合）

来源: e-Century Publishing Corporation

【 摘 要 】

Background: Recent studies have demonstrated associations between ABO blood groups and prognosis in various types of cancers. The aim of this study was to investigate the association between ABO blood groups and biochemical recurrence (BCR) after radical prostatectomy (RP). Methods: A total of 555 patients with prostate cancer who underwent RP were included in the study. No patients received neoadjuvant and/or adjuvant therapy. The effect of ABO blood groups on BCR was examined using univariate and multivariate analyses. Results: During the follow-up period (mean, 52.0 months), 166 patients (29.9%) experienced BCR, with a 5-year BCR-free rate of 67.3%. Although the ABO blood group was not a significantly associated with BCR in the univariate analysis, it was an independent predictor of BCR in the multivariate analysis: blood type O patients had a significantly lower risk of BCR compared to type A patients (Hazard ratio, 0.608; 95% confidence interval, 0.410-0.902; P = 0.014). Further analyses revealed that surgical margin status confounded the assessment of the association between the ABO blood group and BCR. In the analyses of patients with a negative surgical margin, the 5-year BCR-free rate in blood type O patients was a significantly higher than that in type A patients (91.2% vs. 71.0%; P = 0.026). Conclusion: Blood type O is significantly associated with a decreased risk of biochemical recurrence after radical prostatectomy. Further studies are needed to clarify the nature of this association.

【 授权许可】

Unknown